Answers are grounded in this paper and cite their sources.
Recombinant follicle-stimulating hormone (FSH)-based drugs Rekovelle® and Gonal-F® are produced in different host cell lines, i.e. the genetically modified human fetal retinal cell line (PER.C6®) and Chinese hamster ovary (CHO), respectively. Source cells lead to hormone preparations with distinct glycosylation profiles, possibly impacting the pattern of hormone-mediated intracellular signaling cascades. In this study, we compared the preparation-specific intracellular signalling pattern and receptor internalization in vitro. In transfected HEK293 cells expressing the FSH receptor (FSHR), we found that Rekovelle® is more potent than Gonal-F® in activating dose-dependent intracellular cAMP and CRE promoter activity, as an issue detectable in the nM concentrations range. Interestingly, Rekovelle® had a biphasic behaviour on the cAMP-pathway, since the 1 μM drug concentration (33.3 μg/ml) leads to inhibition of cAMP and CRE response, which did not occur with the equimolar Gonal-F® concentration. This event was accompanied by recruitment of β-arrestin 2 and FSHR routing to the late endosomes. To evaluate whether cAMP and CRE inhibition by 1 μM Rekovelle® depends on FSHR internalization, FSH dose-response experiments were performed in β-arrestin 2 knockout HEK293 cell line, where 1 μM Rekovelle® resulted in an intracellular cAMP increase. In conclusion, we found the mechanism underlying different modes of action between follitropin alfa and delta, as an issue likely linked to different glycan profiles, supporting the rationale for a tailored clinical use of these drugs.
No takes yet. Share an insight, caveat, or question.
Lazzaretti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: